Table 2 Adverse events.

From: Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor

AEa, n (%)

Milvexian only

(n = 16)

Milvexian co-administered with single-dose rifampin

(n = 16)

Milvexian following repeated doses of rifampin

(n = 16)

Total

(N = 16)

Any AE

1 (6.3)

4 (25.0)

0

5 (31.3)

Chromaturia

0

3 (18.8)

0

3 (18.8)

Headache

0

1 (6.3)

0

1 (6.3)

Lip dry

1 (6.3)

0

0

1 (6.3)

  1. AE, adverse event; SAE, serious adverse event.
  2. aIncludes on-treatment SAEs within 30 days after the last dose and nonserious AEs within 3 days of the last dose.
Back to article page